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Summary 
Opioid agonist therapy (OAT) was associated with increased HCV testing and treatment among 
PWID, but not treatment completion or sustained virologic response. This supports the scale-





Background: People who inject drugs (PWID) experience barriers to accessing testing and 
treatment for hepatitis C virus (HCV) infection. Opioid agonist therapy (OAT) may provide an 
opportunity to improve access to HCV care. This systematic review assessed the association 
of OAT and HCV testing, treatment, and treatment outcomes among PWID. Methods: 
Bibliographic databases and conference presentations were searched for studies assessing the 
association between OAT and HCV testing, treatment, and treatment outcomes [direct-acting 
antiviral (DAA) therapy only] among people who inject drugs (in the past year). Meta-analysis 
was used to pool estimates. Results: Among 9,877 articles identified, 22 studies conducted in 
Australia, Europe, North America, and Thailand were eligible and included. Risk of bias was 
serious in 21 studies and moderate in one study. Current/recent OAT was associated with an 
increased odds of recent HCV antibody testing [4 studies; odds ratio (OR), 1.80; 95% CI:1.36, 
2.39), HCV RNA testing among those who were HCV antibody positive (2 studies; OR, 1.83; 
95% CI:1.27, 2.62), and DAA treatment uptake among those who were HCV RNA positive (7 
studies; OR 1.53; 95% CI: 1.07, 2.20). There was insufficient evidence of an association 
between OAT and treatment completion (9 studies) or sustained virologic response following 
DAA therapy (9 studies). Conclusions: Opioid agonist therapy can increase linkage to HCV 
care, including uptake of HCV testing and treatment among PWID. This supports the scale-up 







Globally, 6.1 million people who inject drugs (PWID) are estimated to be living with hepatitis 
C virus (HCV) infection [1, 2]. The development of simple, effective direct-acting antiviral 
treatments (DAA) for the treatment of HCV infection [3] has been transformative, with 
evidence that DAAs are having a population-level impact on liver disease burden in settings 
where treatment scale-up has been broad at the population-level [4-7]. The World Health 
Organization (WHO) has set a goal to eliminate HCV infection as a global public health threat 
[8]. However, in many settings, HCV testing and treatment uptake remain below the WHO 
elimination targets, especially among PWID [8]. People who have injected drugs comprise the 
majority of existing infections in many countries [1, 2, 9]. Strategies to improve HCV testing 
and treatment outcomes for PWID, therefore, are critical for global HCV elimination efforts.  
 
Opioid agonist therapy (OAT) improves antiretroviral therapy outcomes for HIV infection [10] 
and reduces risk of HIV and HCV acquisition [11, 12]. It is hypothesized that OAT may 
similarly increase engagement of PWID in the HCV care cascade. Although there are studies 
evaluating the uptake of HCV testing [13-20] and treatment uptake [14, 16, 20-24] among 
PWID, to our knowledge, the association between OAT and HCV testing, treatment uptake 
and treatment outcomes has not been systematically reviewed. Understanding the impact of 
OAT on the cascade of HCV care is critical to inform the implementation of successful 
strategies to enable progress towards global HCV elimination efforts among PWID.  
 
In order to address this gap, we conducted a systematic review: 1) to evaluate the association 
between OAT and HCV testing and treatment uptake among PWID; and 2) to evaluate the 
association between OAT and adherence, treatment completion and sustained virologic 









We included observational (cohorts and cross-sectional studies) or experimental studies 
investigating HCV testing and treatment, if the study met the following criteria: population  of 
people with recent injecting drug use (injecting in the previous 12 months, including 
active/ongoing/current drug use); reported a comparison of outcomes among people who had 
and had not received OAT with either methadone or buprenorphine [ever or currently/recently 
(past 6 months)]; and reported one of the following outcomes: HCV antibody testing [ever or 
recently (past year)], HCV RNA testing [ever or recently (past year)], HCV treatment uptake 
(interferon-based and DAA), and DAA HCV treatment outcomes (adherence, completion, and 
SVR).  
 
Information sources and search 
Literature searches of five bibliographic databases, including Medline (PubMed), Scopus, Web 
of Science, Cochrane Central Register of Controlled Trials (CENTRAL), and PsycINFO were 
performed. Presentations at key viral hepatitis conferences were searched, including the 
International Liver Congress, The Liver Meeting, the Conference on Retroviruses and 
Opportunistic Infections, and the International Conference on Hepatitis Care in Substance 
Users. Reference lists of the articles included in the analysis, and relevant review articles were 
hand searched. Forward citation tracking was carried out using Scopus. Searches were 
performed in September 2018. For searches of HCV testing and treatment uptake, there was no 




published since January 2013 (interferon-free DAA therapies available after this date). 
Combinations of search terms relating to HCV, drug use, OAT, HCV testing, and treatment 
were used (Appendix, pp. 2-3). 
 
   
 
Study selection 
Records identified through primary searches were screened by title and abstract after the 
removal of duplicates. The full text of potentially eligible records were retrieved, reviewed, 
and eligible studies included. In the case of multiple publications of one study, the one with the 
most up-to-date data was included. 
 
Data collection process and data items 
Data extracted included study characteristics, participant characteristics, testing outcomes, 
treatment uptake, and treatment outcomes (Appendix pp 4-7). Authors were contacted if 
supplementary data were required and updated/unpublished data were used in analyses.  
 
Risk of bias in individual studies 
The risk of bias for the included studies was assessed using the Risk Of Bias In Non-
randomised Studies of Interventions (ROBINS-I) tool [26]. Studies were ranked as having low, 
moderate, serious, or critical risk of bias across seven domains, and the overall risk of bias was 
derived. 
 
Study selection, data extraction, and risk of bias appraisal was undertaken by two reviewers 




bias appraisal: HV and LT), with discrepancies discussed with a third reviewer (study 
selection:LD; data extraction: BH; and risk of bias appraisal: LD). 
 
Synthesis of results 
The primary outcomes of interest were recent or ever HCV antibody testing, recent or ever 
HCV RNA testing (among those HCV antibody positive), HCV treatment uptake (among those 
HCV RNA positive), and DAA treatment outcomes (adherence, completion and SVR). 
Treatment completion was defined as completion of the full course of the prescribed treatment 
among those who initiated treatment. SVR was defined as unquantifiable HCV RNA at 12 or 
24 weeks after the end of treatment for those who initiated treatment (intent-to-treat). The 
proportion of people with each outcome of interest was assessed and odds ratios (OR) were 
calculated for the association between: 1) ever having received OAT; and 2) currently received 
OAT on each outcome. For HCV treatment uptake, additional analyses were performed to 
evaluate the association between OAT and DAA treatment. For each study, the outcome 
measures and corresponding standard errors and 95% confidence intervals (95% CI) were 
calculated.  
 
Meta-analysis was used to synthesize the outcome measure estimates. Heterogeneity across 
studies was assessed using the I2 statistic, with an I2 of less than 25%, 25–75%, and more than 
75% considered as low, moderate, and high heterogeneity, respectively [27]. Random effect 
models were used when heterogeneity was medium or high (I2≥25%).  
 
Logit transformed outcome estimates were used in all meta-analyses, while the estimates were 




was a zero cell in calculating ORs. Two-sided p values of less than 0.05 were deemed to be 







A total of 9,877 records in bibliographic databases and 12 records from other sources were 
identified, with 22 studies included (Figure 1) [13-24, 28-37].  
 
Study characteristics are summarized in Tables 1, 2 and Supplementary Table 1 (appendix pp 
27). We identified 9 published studies that measured the impact of exposure to OAT on having 
ever received HCV antibody testing (ever OAT, 7 studies [14, 16-19, 28]; recent OAT, 7 
studies [13, 14, 16-18, 20, 28]) or recently received HCV antibody testing (ever OAT, 3 studies 
[18, 28]; recent OAT, 4 studies [15, 18, 20, 28]; Table 2). We identified 5 published studies 
that measured the impact of exposure to OAT on having ever received HCV RNA testing (ever 
OAT, 5 studies [14, 16, 17, 28]; recent OAT, 5 studies [14, 16, 17, 20, 28]; Table 2) or recently 
received HCV RNA testing among those HCV antibody positive (ever OAT, 2 studies [28]; 
recent OAT, 2 studies [20, 28]; Table 2). We identified 8 published studies that measured the 
impact of exposure to OAT on having ever received HCV treatment among those HCV RNA 
detectable (ever OAT, 6 studies [14, 16, 20-22, 28]; recent OAT, 7 studies [14, 16, 20, 21, 23, 
24, 28]; Table 2). We identified 9 published studies that measured the impact of exposure to 
recent OAT on DAA treatment completion (9 studies) and SVR (9 studies; Supplementary 
Table 1) (none of these studies included data on ever OAT) [29-37]. There was insufficient 
data on adherence to include this outcome.  
 
Description of studies 
Tables 1-2 and Supplementary Table 1 summarize the characteristics of the included studies 
undertaken in Australia (n=10), Canada (n=4), France (n=1), Georgia (n=1), Italy (n=1), 
Thailand (n=1), Ukraine (n=1), and the United States (n=2). Twenty studies were observational 




an interventional trial (Table 1). Definition of recent injecting drug use, proportion ever 
receiving OAT (52-88%), and proportion recently/currently receiving OAT (25-73%) varied 
across studies.  
 
Risk of Bias 
Risk of bias was serious in 21 studies and moderate in one study (Appendix, pp. 18-20). The 
domains that were most often associated with serious risk of bias included bias due to 
confounding and bias in the selection of participants. For all other risk of bias domains most 
studies were rated as being at low risk of bias. It was not appropriate to conduct sensitivity 
analyses (e.g. excluding studies at serious/critical risk of bias) because all but one study met 
this criteria. 
 
Impact of OAT on HCV antibody testing 
Across 8 studies, the proportion of people who ever received HCV antibody testing was 
between 33% and 94% (Table 2). Studies were pooled measuring the impact of ever having 
received OAT (7 studies) and recently/currently receiving OAT (7 studies) on having ever 
received HCV antibody testing (Figure 2). Random-effect meta-analysis of estimates 
demonstrated that having ever received OAT was associated with an increased odds of having 
ever received HCV antibody testing (OR=2.74; 95% CI 1.70, 4.40; I2=86.0%). Recent exposure 
to OAT was associated with an increased odds of having ever received HCV antibody testing 
(OR=2.26; 95% CI 1.80, 2.85; I2=37.2%)). 
 
The proportion who recently received HCV antibody testing was between 48% and 71% (Table 
2). We also pooled data from studies measuring the impact of ever having received OAT (3 




antibody testing (Figure 2). Having ever received OAT was associated with an increased odds 
of recent HCV antibody testing (OR=2.12; 95% CI 1.07, 4.20; I2=75.7%). Recent exposure to 
OAT was associated with an increased odds of recent HCV antibody testing (OR=1.81; 95% 
CI 1.40, 2.34; I2=12.6%).  
 
Impact of OAT on HCV RNA testing 
The proportion of people who had ever received HCV RNA testing among those who were 
HCV antibody positive was between 35% and 89% (Table 2). Studies were pooled measuring 
the impact of ever having received OAT (5 studies) and recently/currently receiving OAT (5 
studies) on having ever received HCV RNA testing (Figure 2). Having ever received OAT was 
associated with an increased odds of having ever received HCV RNA testing (OR=2.14; 95% 
CI 1.55, 2.95; I2=69.3%). Recent OAT exposure was associated with an increased odds of 
having ever received HCV RNA testing (OR=1.74; 95% CI 1.29, 2.35; I2=71.4%).   
 
The proportion who had recently received HCV RNA testing was 44% in one study and 45% 
in the other study (Table 2). We pooled data from studies measuring the impact of ever having 
received OAT (2 studies) and having recently/currently receiving OAT (2 studies) on having 
recently received HCV RNA testing (Figure 2). Having ever received OAT was not associated 
with an increased odds of having recently received HCV RNA testing (OR= 2.38; 95% CI 0.94, 
6.07; I2=90.5%). Having recently received OAT was associated with an increased odds of 
having received HCV RNA testing (OR=1.83; 95% CI 1.28, 2.61; I2=49.8%). 
 
Impact of OAT on HCV treatment uptake 
The proportion of people who had ever received HCV treatment among those who were HCV 




of ever having received OAT (6 studies; DAA: 4 studies) and recently/currently receiving OAT 
(7 studies; DAA: 5 studies) on having ever received HCV treatment were pooled (Figure 3). 
The association of having ever received OAT and having ever received HCV treatment was 
not statistically significant (OR=1.53; 95% CI 0.92, 2.55; I2=86.3%). Recent OAT exposure 
was associated with an increased odds of having ever received HCV treatment (OR=1.56; 95% 
CI 1.07, 2.26; I2=82.3%). The intervention association strengthened and heterogeneity 
decreased when only studies in the DAA era were considered (6 studies; OR=1.83; 95% CI 
1.51, 2.21, I2=0.0%).  Having ever received OAT was associated with an increased odds of 
having ever received DAA HCV treatment (OR=2.15; 95% CI 1.67, 2.76, I2=0.0%) (4 studies). 
 
Impact of OAT on HCV treatment completion and SVR 
The proportion of people who had completed HCV treatment among those who initiated HCV 
treatment was between 65% and 100% and the proportion that had achieved SVR was between 
64% and 94% (Supplementary Table 1). We pooled data from studies measuring the impact of 
recently/currently receiving OAT on having completed HCV treatment (9 studies) or having 
achieved an SVR (9 studies) (Figure 4). There was no impact of having recently received OAT 
on treatment completion (OR=1.25; 95% CI 0.57, 2.76, I2=54.2%) or SVR (OR=0.79; 95% CI 
0.42, 1.51, I2=62.1%).  
DISCUSSION 
We found evidence of an association between recent OAT exposure and ever receiving OAT 
on HCV testing and treatment uptake among PWID. Recent OAT was not associated with DAA 
treatment completion or SVR. These data have important implications for clinical management 
and health policy, supporting the integration of services for the treatment of opioid dependence 





OAT was associated with improvements in HCV testing and treatment uptake, consistent with 
literature demonstrating that OAT reduces harms across multiple health outcomes for people 
who are opioid dependent [38]. OAT improves engagement in HIV treatment, adherence, and 
virologic suppression [10]. OAT is also associated with reductions in injecting risk behavior 
[39], risk of HIV and HCV infections [11, 12], criminal activity [40], and all-cause [41] and 
overdose [41] mortality. It is unsurprising that current OAT was not associated with DAA 
treatment completion or SVR, given the high proportion of PWID who complete and respond 
to DAA therapy [42].  
 
The mechanism behind the association between OAT and improvements in HCV testing and 
treatment is likely multifactorial, relating to the interplay between system-, provider-, social-, 
and patient-level factors. Most people receiving OAT attend drug treatment clinics or 
community health centers providing services other than OAT, including other medical care 
(including HCV), mental health services, and vocational and other assistance. People receiving 
OAT often have regular contact with health services with persistent cues for engagement and 
education [43], offering increased opportunities for engaging in HCV education, testing and 
treatment, particularly when services are integrated and on-site [44].  
 
Qualitative interviews with people receiving and providing services in drug treatment clinics 
have highlighted key facilitators for engagement in HCV care [43, 45-50]. In drug treatment 
settings, engagement in HCV care is facilitated by existing relationships of trust between 
people receiving OAT and their healthcare providers [45-49], with HCV care providing 
opportunities to strengthen therapeutic relationships [50]. People using drug treatment services 
report that the provision of HCV testing and treatment on-site allows more immediate and 




from OAT to off-site hospital-based models of HCV care [48], which may be associated with 
negative, stigmatizing or discriminatory experiences [43, 46]. People receiving OAT also 
highlight that drug treatment clinics offer the potential for greater familiarity [46, 47, 50], 
flexibility [46], and convenience through on-site care (including reduced travel time and costs) 
[43, 46-50].  
 
Integration of OAT and HCV has been shown to be highly acceptable to both clients and staff 
[51]. In a study of people with ongoing injecting drug use and opioid dependence offered HCV 
and buprenorphine treatment, 79% (53 of 67) not receiving OAT at baseline subsequently 
initiated buprenorphine during HCV therapy, with reductions in injecting risk observed among 
those receiving OAT [52]. Integration of OAT and HCV services can occur in a range of 
settings where people are already accessing health services (e.g. drug treatment clinics, HIV 
clinics, harm reduction services) in combination with different interventions (e.g. financial 
incentives, telemedicine, peer-based support) [13, 44]. No one size will fit all, with models of 
care requiring person-centric approaches . However, key barriers to HCV treatment among 
PWID must be addressed, include stigma, housing, criminalisation, and health care systems 
[54] . 
 
Major strengths of this study include synthesizing estimates for the association of OAT with 
components of the HCV cascade of care among PWID and the supplementary data included 
through contacting authors. Key limitations of the evidence include the small number of studies  
and that the majority of studies were from one country (Australia). Most studies were at serious 
risk of bias due to the potential for confounding and biases in the selection of participants into 
the studies. The control of confounders was limited and inconsistent across the studies. As 




meta-regression to explore sources of heterogeneity. The majority of studies identified were 
cross-sectional and the effect of residual confounding on OAT and components of the HCV 
cascade of care cannot be ruled out. People who accessed OAT may also have been more likely 
to have characteristics which may have led to increased HCV testing and treatment uptake. 
Since most studies were cross-sectional, it is possible that OAT use may not have preceded the 
outcome. This temporality of the association between the exposure (OAT) and outcome (HCV 
testing and treatment) is a limitation. We cannot, therefore, assume that OAT use commenced 
before, rather than after, HCV testing or treatment. The impact of OAT on HCV testing and 
treatment uptake at a population level will also be determined by the proportion of PWID 
within that population with opioid dependence. Although the majority of studies had a high 
proportion of participants with a history of opioid use, not all participants may have been opioid 
dependent and/or required OAT. This misclassification bias may have overestimated of the 
observed association between OAT and HCV outcomes.  
 
In conclusion, this study demonstrated that recent OAT was associated with improvements in 
HCV testing and treatment uptake, supporting the integration of HCV services in drug 
treatment settings. This study also provides important information to inform mathematical 
modelling of interventions to enhance HCV care among PWID. Further work is needed to 
understand strategies to optimize HCV testing and treatment within drug treatment settings and 
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Table 1. Characteristics of the studies included in the analysis 






Study design    
Observational, prospective  7 (32%) 2,016 
Observational, retrospective  5 (23%) 1,539 
Cross-sectional  8 (36%) 14,236 
Clinical trials 2 (10%) 305 
Study setting    
Community clinic  3 (14%) 437 
Tertiary care 3 (14%) 431 
Needle and syringe programs 5 (23%) 10,357 
Mixed 6 (27%) 3,730 
Other/not reported  5 (23%) 2,953 
Number of Centres    
Single-centre  8 (35%) 1,359 
Multicentre  14 (64%) 16,549 
Definition of recent drug use1    
During the past 1 month  3 (14%) 1,323 
During the past 6 months  14 (64%) 6,223 
During the past 12 months  2 (9%) 301 
Ongoing or active drug use  4 (18%) 10,713 
Definition of opioid substitution therapy1    
Current 20 (91%) 8,574 
Past 6 months  1 (5%) 345 
Ever 8 (36%) 10,867 






Table 2. Characteristics of included studies and reported outcomes for HCV antibody, HCV RNA testing, and treatment uptake 
HCV antibody testing 
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HCV treatment uptake 





































































































































































Figure 1. PRISMA flowchart 
Figure 2. Forest plots examining the association between OAT and HCV antibody and RNA 
testing 
Figure 3. Forest plots examining the association between OAT and HCV treatment uptake 
Figure 4. Forest plots examining the association between OAT and HCV treatment completion 
and SVR 
 
